International First-in-Human Study of the EnligHTN Generation 2 System in Patients With Drug-resistant Uncontrolled Hypertension

Inclusion Criteria: * Subject is ≥ 18 and ≤ 80 years of age at time of consent * Subject must be able and willing to provide written informed consent * Subject must be able and willing to comply with the required follow-up schedule * Subject has office Systolic Blood Pressure ≥ 160 mmHg at confirmatory visit * Subject has a daytime mean Systolic Ambulatory Blood Pressure \> 135 mmHg during the two week screening period * Subject has an office Systolic Blood Pressure that remains ≥160 mmHg despite the stable use of ≥3 antihypertensive medications concurrently at maximally tolerated doses, of which one is a diuretic or subject was previously on diuretic but documented to be diuretic intolerant, for a minimum of 14 days prior to the procedure and with an expectation to maintain for a minimum of 180 days post procedure. Exclusion Criteria: * Subject has significant renovascular abnormalities such as renal artery stenosis \> 30% in either renal artery * Subject has undergone prior renal angioplasty, renal denervation, indwelling renal stents, and/or abdominal aortic stent grafts * Subject has hemodynamically significant valvular heart disease as determined by the Study Investigator * Subject has a life expectancy less than 12 months, as determined by a Study Investigator * Subject is participating in another clinical study which has the potential to impact their hypertension management (pharmaceutical/device/homeopathic) * Subject is pregnant, nursing, or of childbearing potential and is not using adequate contraceptive methods * Subject has active systemic infection * Subject has renal arteries with diameter(s) \< 4 mm in diameter or \<20 mm in length * Subject has an estimated Glomerular Filtrate Rate (eGFR) \<45 mL/min per 1.73 m2 using the Modified Diet in Renal Disease (MDRD) formula * Subject has Diabetes Mellitus Type I * Subject has multiple main renal arteries in either kidney * Subject has an identified secondary cause of hypertension (for example, including, but not limited to, Polycystic kidney disease, Cushing's syndrome, Aldosteronism) * Subject has evidence of significant abdominal aortic aneurysm (defined as maximum diameter of \>4 cm) * Subject has had a myocardial infarction, unstable angina pectoris or cerebrovascular accident less than 180 days prior to enrollment * Subject is expected to have cardiovascular intervention within the next 180 days * Subject has a condition which would interfere with the accurate interpretation of the study objectives including but not limited to a large arm diameter that is unable to accommodate the blood pressure cuff or arrhythmia that interferes with automatic pulse sensing.